Search
Now showing items 1-6 of 6
Age-dependent decrease in glutamine synthetase expression in the hippocampal astroglia of the triple transgenic Alzheimer's disease mouse model : mechanism for deficient glutamatergic transmission?
(BioMed Central, 2011-07-30)
Astrocytes are fundamental for brain homeostasis and the progression and outcome of many neuropathologies including Alzheimer's disease (AD). In the triple transgenic mouse model of AD (3xTg-AD) generalised hippocampal ...
Early astrocytic atrophy in the entorhinal cortex of a triple transgenic animal model of Alzheimer's disease
(Portland Press, 2011)
The EC (entorhinal cortex) is fundamental for cognitive and mnesic functions. Thus damage to this area appears as a key element in the progression of AD (Alzheimer's disease), resulting in memory deficits arising from ...
Brca1 is expressed in human microglia and is dysregulated in human and animal model of ALS
(Biomed Central, 2015-08-01)
Background: There is growing evidence that microglia are key players in the pathological process of amyotrophic lateral sclerosis (ALS). It is suggested that microglia have a dual role in motoneurone degeneration through ...
Increased expression of cystine/glutamate antiporter in multiple sclerosis
(BioMed Central, 2011-06-03)
Background: Glutamate excitotoxicity contributes to oligodendrocyte and tissue damage in multiple sclerosis (MS). Intriguingly, glutamate level in plasma and cerebrospinal fluid of MS patients is elevated, a feature which ...
A novel form of human disease with a protease-sensitive prion protein and heterozygosity methionine/valine at codon 129: Case report
(BioMed Central, 2010-10)
Background: Sporadic Creutzfeldt-Jakob disease (sCJD) is a rare neurodegenerative disorder in humans included in the group of Transmissible Spongiform Encephalopathies or prion diseases. The vast majority of sCJD cases are ...
FTY720 attenuates excitotoxicity and neuroinflammation
(BioMed Central, 2015-05-08)
Background: FTY720 (fingolimod, Gilenya(TM)), a structural analog of sphingosine-1-phosphate (S1P), is the first oral drug approved for treatment the relapsing-remitting form of multiple sclerosis (MS), and its efficacy ...